After decades of attempts to develop treatments for Alzheimer’s disease, scientists still have precious little to show for it. Now, after some high-profile failures, there are big questions about where researchers can turn next.
Join STAT senior science writer Sharon Begley and STAT senior medicine writer Matt Herper for a subscriber-only live chat on Alzheimer’s research, the beta-amyloid theory, and the effort to develop new therapies. They’ll also be discussing the latest news out of the Alzheimer’s Association International Conference.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Authors
